Mark E. Shirtliff, Ph.D.

Microbial Pathogenesis

CLICK ARTICLE TO DOWNLOAD PDF

Peters BM, Ovchinnikova E., Jabra-Rizk MA, Hoyer L, van der Mei HC, Busscher HJ, Krom BP, and Shirtliff ME. Candida albicans hyphal adhesin Als3p mediates interspecies interactions with Staphylococcus aureus during polymicrobial biofilm growth. 2011. – submitted  to PLoS One.

Cope E, Goldstein-Daruech N, Kofonow J, Christensen L, Gilliland M, McDermott B, Monroy F, Nunamaker J, Palmer J, Chiu A, Cohen N, Shirtliff ME, and Leid JG. Characterization of virulence gene expression resulting from Streptococcus pneumoniae and nontypeable Haemophilus influenzae polymicrobial interactions in a chronic disease. 2011. – submitted  to PLoS One.

Zhu J, Krom B, Peters B, Shirtliff ME, Scheper M, Intapa C, Jabra-Rizk MA. Farnesol-induced apoptosis in Candida albicans is mediated by Cdr1-p extrusion and depletion of intracellular glutathione. J Euk Cell. 2011. – accepted with revisions.

Conti S, Sotereanos N, Altman G, Altman D, Post JC, Ehrlich GD, Gorur A, Schaudinn C, Sedghizadeh P, Shirtliff ME, Costerton JW, Stoodley P, Kathju S, and DeMeo P. Significance of the biofilm mode-of-growth in orthopaedic infections. JBJS. 2011. – in press.

Cope E, Cohen N, Dowd SE, Palmer J, Chiu A, Wolcott R, Neeling L, Gmerek A, Smith A, Shirtliff ME, and Leid JG. Primary exposure to cigarette smoke influences microbial community composition in chronic rhinosinusitis determined by next generation pyrosequencing. FEMS Med Micro Immun. 2011. – in press.

O’May GA, Macfarlane S, Macfarlane GT, and Shirtliff ME. Biofilms in the human gastrointestinal tract. 2011 – in press.

Stoodley P, Hall-Stoodley L, Costerton JW, DeMeo P, Shirtliff ME, Gawalt E, and Kathju S. Biofilms, Biomaterials, and Device-Related Infections. In Biomaterials. 2011. – in press.

Han A, Zenilman JM, Melendez JH, Shirtliff ME, Agostinho A, James G, Stewart PS, Mongodin EF, Rao DL, Rickard AH, Lazarus GS. A systematic, multi-faceted approach using novel molecular methods to characterize the microbial flora in chronic wounds. 2011. Wound Rep. Regen. – in press.

Peters BM, O’May GA, Jabra-Rizk MA, Costerton JW, and Shirtliff ME. Polymicrobial interactions in biofilms: impact on pathogenesis and human disease. Clin Micro Rev. 2011. – in press.

Xu Z, Lin L, Chu J, Peters BP, Harris ML, Li B, Shi L, and Shirtliff ME. Development and application of loop-mediated isothermal amplification assays on rapid detection of various types of staphylococcal strains. Food Res Int.  – in press.

Xu Z, Lin Li L, Shirtliff ME, Peters BM, Li B, Peng Y, Alam MJ, Yamasaki S, Shi L. Resistance Class 1 Integron in clinical methicillin-resistant Staphylococcus aureus strains in Southern China, 2001-2006. Clin Microbiol Infect. 17(5):714-8, 2011.

Prabhakara R, Harro J, Harris M, Leid JG, and Shirtliff ME. Prevention and resolution of Staphylococcus aureus biofilm infections via host immune response modulation. Infect Immun. Epub: Sept 26, 2011.

Jacobsen SM and Shirtliff ME. Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence. Sep 1;2(5). 2011.

Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, and Shirtliff ME. Staphylococcus aureus biofilms: Properties, regulation, and roles in human disease. Virulence. Sep 1;2(5), 2011.

Prabhakara R, Harro JM, Leid JG, Harris ML, and Shirtliff ME. Murine immune response to a chronic Staphylococcus aureus biofilm infection. Infect Immun. 79(4): 1789-1796, 2011.

Brady RA, O’May G, Leid JG, and Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun. 79(4): 1797-1803, 2011.

Xu Z, Li L, Shi L, Shirtliff ME. Class 1 integron in staphylococci. Mol Biol Rep. Published online: Jan 22, 2011.

Peters BM, Shirtliff ME, Jabra-Rizk MA. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog. 2010. 28;6(10):e1001067.

Zhao X, Wang L, Chu J, Li Y, Li Y, Xu Z, Li L, Shirtliff ME, He X, Liu Y, Wang J, and Yang L. Rapid detection of Vibrio parahaemolyticus strains and virulent factors by loop-mediated isothermal amplification assays. Food Sci Biotechnol. 2010. 19(5):1191-1197.

Xu Z, Li L, Shirtliff ME, Peters BM, Peng Y, Alam MJ, Yamasaki S, Shi L. First report of class 2 integron in clinical Enterococcus faecalis and class 1 integron in Enterococcus faecium in South China. Diagn Microbiol Infect Dis. 2010. 68(3):315-7.

Miclau T, Schmidt AH, Wenke JC, Webb LX, Harro JM, Prabhakara R, Shirtliff ME. Infection. J Orthop Trauma. 2010 Sep;24(9):583-6.

Donelli G, Bayston R, Costerton WB, Shirtliff ME. The first European congress on microbial biofilms: EUROBIOFILMS 2009, Rome, Italy, September 2-5, 2009. FEMS Immunol Med Microbiol. 2010. 59(3):223-6.

Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW, Shirtliff ME. Microbial interactions and differential protein expression in Staphylococcus aureus -Candida albicans dual-species biofilms. FEMS Immunol Med Microbiol. 2010. 59(3):493-503.

Harro JM, Peters BM, O'May GA, Archer N, Kerns P, Prabhakara R, Shirtliff ME. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol Med Microbiol. 2010. 59(3):306-23.

Calhoun JH, Manning M, and Shirtliff ME. Osteomyelitis of the long bones. Sem. Plastic Surg. 23(2):59-72. 2009.

Shirtliff ME, Peters B, Jabra-Rizk MA. Cross-kingdom interactions: Candida albicans and Bacteria. FEMS Microbiol Lett. 299(1): 1-8, 2009.

Unnanuntana A, Bonsignore L, Shirtliff ME, and Greenfield EM. The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts. An in vitro study. J Bone Joint Surg Am.;(91):2683-92, 2009.

Leid JG, Kerr M, Selgado C, Johnson C, Moreno G, Shirtliff ME, O’Toole GA, and Cope EK. Flagellar-mediated biofilm defense mechanisms of Pseudomonas aeruginosa against host derived lactoferrin. J of Immunology. 77(10):4559-66, 2009.

Shirtliff ME, Krom BP, Peters B, Zhu J, and Jabra-Rizk MA. Farnesol-induced modifications in Candida albicans proteome. Antimicrob  Agents Chemother. 53(6):2392-401, 2009.

O’May G, Jacobsen SM, Mobley H, and Shirtliff ME. The high-affinity phosphate transporter Pst in Proteus mirabilis HI4320 and its importance in biofilm formation. Microbiology. 155(5):1547-1557, 2009.

Meiller TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Ton A, and Jabra-Rizk MA. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS ONE. 4(4):e5039, 1-9, 2009.

Xu Z, Li L, Shirtliff ME, Alam MJ, Yamasaki S, Shi L. Occurrence and characteristics of class 1 and 2 integrons in Pseudomonas aeruginosa isolates from patients in southern China. J Clin Microbiol. 47(1):230-4, 2009.

Scheper MA, Shirtliff ME, Meiller TF, Peters B, and Jabra-Rizk MA. Farnesol a fungal quorum sensing molecule triggers apoptosis in human oral squamous carcinoma cells. Neoplasia. 10(9):954-63, 2008.

Jacobsen SM, Lane MC, Harro JM, Shirtliff ME*, and Mobley HLT*. *Both authors contributed equally. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection. FEMS Immun Med Micro. 52(2):180-93, 2008.

Jacobsen SM, Stickler D, Mobley HLT, and Shirtliff ME. The role of Escherichia coli and Proteus mirabilis in catheter-related urinary tract infections. Clin Micro Rev. 21(1):26-59, 2008.

Brady R, Leid JG, Calhoun JH, and Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immun Med Micro. 52:13-22, 2008.

Brady RA, Leid JG, Kofonow J, Costerton JW, and Shirtliff ME. Immunoglobulins to surface-associated biofilm immunogens provide a novel means of visualization of methicillin-resistant Staphylococcus aureus biofilms. Appl Env Micro. 73(20): class="pages"6612-9, 2007.

Lazzarini L, Overgaard KA, Conti E, and Shirtliff ME. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis? J Chemother. 18(5): 451-460, 2006.

Jabra-Rizk MA, Shirtliff M, James C, and Meiller T. Farnesol effect on Candida albicans and Candida dubliensis. FEMS Yeast Research. 6(7):1063-73, 2006.

Brady RA, Leid JG, Costerton JW, and Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibody mediated immune response to a biofilm infection. Infect Immun. 74(6): 3415-3426, 2006.

Jabra-Rizk MA, Meiller T, James CE, and Shirtliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother. 50(4):1463-9 2006.

Brady RA, Leid JG, Costerton JW, and Shirtliff ME. Osteomyelitis. Clin Micro News. 28(9): 65-72, 2006.

Leid JG, Carey JW, Shirtliff ME, Hassett DJ, Parsek MR, and Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-g-mediated macrophage killing. J Imm. 175(11):7512-8, 2005.

Shirtliff ME, Bargmeyer A, and Camper AK. Assessment of the bioelectric effect to eliminate mixed water species biofilms. Appl Environ Micro.71(10):6379-82, 2005.

Fux CA, Shirtliff ME, Stoodley P, and Costerton JW. Can laboratory strains mirror “real world” pathogenesis? Trends Micro. 13(2):2005.

Bargmeyer A, Shirtliff M, Butterfield P, Camper A, Friedman M, and Boyd G. Innovative Biofilm Prevention Strategies. AWWARF Report 91011F. IWA Publishing. June, 2005.

Costerton JW, Veeh R, Shirtliff ME, Pasmore M, Post C, and Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 112(10):1466-1477, 2003.

Worley SD, Li F, Wu R, Wei C-I, Williams JF, Owens J, Wander JD, Bargmeyer AM, and Shirtliff ME. A novel N-halamine monomer for preparing biocidal polyurethane coatings. Surface Coatings Int. Part B: Coat. Trans. 86(B4):273-277, 2003.

Shirtliff ME and Mader JT. Imaging in osteomyelitis. Curr Treat Options Infect Dis 5(4):323-335, 2003.

Veeh RH, Shirtliff ME, Petik JR, Flood JA, Davis CC, Seymour JL, Hannsmen MA, Kerr KM, Costerton JW, and Pasmore, M. Detection of Staphylococcus aureus biofilm on tampons and menses. J Infect Dis. 188(4):519-530, 2003.

Shirtliff ME, Mader JT, and Camper AK. Molecular interactions in biofilms. Chem and Biol. 9(8):859-865, 2002.

Shirtliff ME and Mader JT. Acute septic arthritis. Clin Micro Rev. 15(4):527-544, 2002.

Chen JJ, Huang JC, Shirtliff M, Briscoe E, Ali S, Cesani F, Paar D, Cloyd MW. CD4 lymphocytes in the blood of HIV(+) individuals migrate rapidly to lymph nodes and bone marrow: support for homing theory of CD4 cell depletion. J Leukoc Biol. 72(2):271-8, 2002

Leid JG, Costerton JW, Shirtliff ME, Gilmore MS, and Engelbert M. Immunology of staphylococcal biofilm infections in the eye: New tools to study endophthalmitis. J DNA Cell Biol. 21(5):405-413, 2002.

Shirtliff ME, Calhoun JH, and Mader JT. Experimental osteomyelitis treatment with antibiotic-impregnated hydroxyapatite. Clin Orth Related Res. 401:239-247, 2002.

Leid JG, Shirtliff ME, Costerton JW, and Stoodley P. Human leukocytes adhere to, penetrate, and respond to S. aureus biofilms. Infect Immun. 70(11): 6339-6345, 2002.

Shirtliff ME, Calhoun JH, and Mader JT. Evaluation of gatifloxacin in the treatment of methicillin sensitive S. aureus osteomyelitis in a rabbit model. Antimicrob Agents Chemother. 46(1):231-233, 2002.

Shirtliff ME, Calhoun JH, and Mader JT. The treatment of experimental methicillin sensitive S. aureus osteomyelitis in rabbits with levofloxacin and nafcillin. J Antimicrobial Chemother. 48(2):253-258, 2001.

Balaban N, Collins LV, Cullor JS, Hume EB, Medina-Acosta E, Vieira da Motta O, O'Callaghan R, Rossitto PV, Shirtliff ME, Serafim da Silveira L, Tarkowski A, and Torres JV. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides. 21(9):1301-1311, 2000.

Mader JT, Shirtliff ME, Bergquist S, and Calhoun JH. Bone and joint infections in the elderly. Practical treatment guidelines. Drugs & Aging. 10(1):1170-1185, 2000.

Mader JT, Shirtliff ME, Bergquist S, and Calhoun JH. Antimicrobial treatment of chronic osteomyelitis. Clin Orth Related Res. 360:47-65, 1999.

Shirtliff ME, Calhoun JH, and Mader JT. Rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. Clin Orth Related Res. 359:229-236, 1999.

Ali SA, Cesani F, Nusynowitz ML, Briscoe EG, Shirtliff ME, Mader JT. Skeletal scintigraphy with technetium-99m-tetraphenyl porphyrin sulfonate for the detection and determination of osteomyelitis in an animal model. J Nuc Med. 38(12):1999-2002, 1997.

Mader JT, Shirtliff ME, and Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis. 25(6):1303-1309, 1997.

Davis CP, Shirtliff ME, Scimeca JM, Hoskins SL, and Warren MM. In vivo reduction of bacterial populations in the urinary tract of catheterized sheep by iontophoresis. J Urol. 154:1948-53, 1995.

Davis CP, Shirtliff ME, Trieff NM, Hoskins SL, and Warren MM. Quantification, qualification, and microbial killing efficiencies of antimicrobial chlorine-based substances produced by iontophoresis. Antimicrob Agents Chemother. 38:2768-74, 1994.

Back to Top

Stoodley P, Hall-Stoodley L, Costerton JW, DeMeo P, Shirtliff ME, Gawalt E, and Kathju S. Biofilms, Biomaterials, and Device-Related Infections. In Biomaterials. 2011. – in press.

Leid JG, Cope EK, Parmenter S, Shirtliff ME, Dowd S, Wolcott R, Basaraba R, Hunsaker H, Palmer J, and Cohen N. The importance of biofilms in chronic rhinosinusitis. Biofilm Infections. Springer Inc. New York, New York. 2010. 139-160.

O’May GA, Brady RA, Leid JG, Calhoun JH, and Shirtliff ME. Osteomyelitis. Biofilm Infections. Springer Inc. New York, New York. 2010. 111-138.

Brady RA, Calhoun JH, Leid JG, and Shirtliff ME. Infections of orthopaedic implants and devices. In: Biofilms and Device-Related Infections. Springer, New York, NY. ed. Shirtliff ME and Leid JG. 15-56, 2009.

Costerton JW, Veeh R, Shirtliff ME, Pasmore M, Post C, and Ehlich G. The application of biofilm science to the study and control of chronic bacterial infections. In: Science in Medicine: The JCI Textbook of Molecular Medicine. ed Marks AR. American Society for Clinical Investigation. Jones and Bartlett, Boston, MA. 121-131, 2009.

O’May G, Jacobsen SM, Mobley H, and Shirtliff ME. Catheter-related urinary tract infections. In: Biofilms and Device-Related Infections. Springer, New York, NY. ed. Shirtliff ME and Leid JG. 123-166, 2009.

M. Nymer M, Cope E, Brady R, Shirtliff ME, and Leid JG. Immune responses to indwelling medical devices. In: Biofilms and Device-Related Infections. Springer, New York, NY. ed. Shirtliff ME and Leid JG. 239-264, 2009.

Fux CA, Stoodley P, Shirtliff ME, and Costerton JW. Biofilms. In: Antimicrobial Drug Resistance: Principles and Practice for the Clinic and Bench. ed Mayers DL. Infectious Disease Series. ed Georgiev VS. Humana Press. March, 2008.

Calhoun JH, Sexton DJ, and Shirtliff ME. Hematogenous osteomyelitis in adults. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2007.

Calhoun J, Christensen G, Brady RA, Shirtliff ME. Osteomyelitis. In: Expert Guide to Infectious Diseases. ed. Tan JS. American College of Physicians-American Society of Internal Medicine. Philadelphia, PA. 2007.

Shirtliff ME, Singh Bal B, Yin L, and Calhoun JH. Staging systems for long bone osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2006.

Shirtliff ME, Cripps MW, and Calhoun JH. Staging systems for long bone osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2005.

Costerton JW, Stoodley P, Shirtliff ME, Pasmore M, Cook G. Biofilms, biomaterials, and device-related infections. In: Biomaterials Science: An Introduction to Materials in Medicine. ed. Ratner BD, Hoffman AS, Schoen FJ, and Lemons JE., Elsevier Academic Press. 345-354, 2004.

Shirtliff ME, Leid J, and Costerton JW. Basic science of musculoskeletal infections. In: Musculoskeletal Infections. ed. Mader JT and Calhoun JH. Marcel Dekker, Inc. New York, NY. 1-61, 2002.

Shirtliff ME and Lefrock J. Septic Arthritis. In: Musculoskeletal Infections. ed. Mader JT and Calhoun JH. Marcel Dekker, Inc. New York, NY. 183-209, 2002.

Mader JT and Shirtliff ME. Osteomyelitis. In: Conn's Current Therapy, 2002 Edition. ed. Rakel RE and Bope ET. WB Saunders Co. Philadelphia, PA. 1010-1016, 2002.

Mader JT, Wang J, Shirtliff ME, and Calhoun J. Osteomyelitis. Expert Guide to Infectious Diseases. ed. Tan JS. American College of Physicians-American Society of Internal Medicine. Philadelphia, PA. 585-604, 2002.

Mader JT, Trevino SG, Galbraith JW, and Shirtliff ME. Osteomyelitis. In: Internal Medicine Pearls, 2^nd Edition. ed. Heffner JE and Sahn SA. Hanley & Belfus, Inc. Philadelphia, PA. 191-195, 2001.

Shirtliff ME and Mader JT. Osteomyelitis: Clinical Features and Molecular Aspects of Persistence. In: Persistent Bacterial Infections. ed. Nataro JP, Blaser MJ, and Cunningham-Rundles S. ASM Press, Washington DC. 375-395, 2000.

Mader JT and Shirtliff ME. The Rabbit Model of Bacterial Osteomyelitis of the Tibia. In: Handbook of Animal Models of Infection. ed. Zak O and Sande MA. Academic Press Ltd. London, England. 581–591, 1999.

Mader JT, Shirtliff ME, and Calhoun JH. Practical guidelines in the diagnosis and treatment of osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 1999.

Mader JT, Shirtliff ME, Bergquist S, and Calhoun JH. Principles of management and treatment of osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 1999.

Mader JT, Shirtliff ME, and Calhoun JH. The host and the skeletal infection: Classification and pathogenesis of acute bacterial bone and joint sepsis. In: Baillière's Best Practice & Research. Clinical Rheumatology. ed. Woolf AD. 13(1):1-20, 1999.

Mader JT, Shirtliff ME, and Calhoun JH. The use of hyperbaric oxygen in the treatment of osteomyelitis. In: Hyperbaric Medicine Practice. Best Publishing Co. Flagstaff, Arizona. 603-616, 1999.

Mader JT, Shirtliff ME, Cripps MW, and Calhoun JH. Staging systems for long bone osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 1998.

Mader JT, Shirtliff ME, Cripps MW, and Calhoun JH. Cierny-Mader staging and the treatment of long bone osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 1998.

Back to Top

Shirtliff ME and Leid JG, Editors. Biofilms and Device-Related Infections. Springer, New York, NY. 2009.

Shirtliff ME, Costerton JW, Bayston R, and Donnelli G. Editor. Eurobiofilms 2009 Thematic Issue. FEMS Immun Med Micro. In Press.

Back to Top

“Understanding biofilms and host pathogen interactions for MRSA vaccine development” Uniformed Services University of Health Sciences. Bethesda, Maryland. January 24, 2011.

“Who’s smarter: The bugs or us?” 2010 Orthopaedic Trauma Association. Baltimore, Maryland. October 16, 2010.

“Biofilms and Biosafety” American Biological Safety Association 2010 Meeting. Denver, Colorado. October 2, 2010.

“Advancements in the fight against biofilms in chronic infections” ATACCC 2010 Conference. St. Petes Beach, Florida. August 17, 2010.

“Diagnosis and vaccine prevention of biofilm-mediated chronic orthopaedic infections.” AOTrauma CPP Bone Infection workshop. Boston, Massachusetts. July 23, 2010.

“MRSA biofilm vaccine.” NIAID Staphylococcal Vaccine Workshop. Bethesda, Maryland. May 10, 2010.

“Novel Approaches for an Antibiofilm S. aureus Vaccine”, 8th World Congress on Trauma, Shock, Inflammation, and Sepsis (TSIS), Munich, Germany. March 9th – 13th, 2010.

“Biofilms in Medical and Dental Infectious II”, Session Chair. 5th ASM Conference on Biofilms. Cancun, Mexico. November 15 - 19, 2009.

“Candida albicans-Staphylococcus aureus dual-species biofilms mediate invasive staphylococcal infection.” 5th ASM Conference on Biofilms. Cancun, Mexico. November 15 - 19, 2009.

“SYMPOSIUM 5: Infection” Session Chair. OTA Annual Meeting - 25th Anniversary Meeting. San Diego, CA. October 8-10, 2009

“Chronic Orthopaedic Infections: Are Vaccines the Answer?” OTA Annual Meeting - 25th Anniversary Meeting. San Diego, CA. October 8-10, 2009

“The Host Immune Response: How Important Is It?” OTA Annual Meeting - 25th Anniversary Meeting. San Diego, CA. October 8-10, 2009

“Views from the host and the pathogen in Staphylococcus aureus anti-biofilm vaccine development.” National Institute of Standards and Technology, Bethesda, Maryland. September 28, 2009.

“Host immune response to biofilm infections.” Co-Organizer and Session Chair. Eurobiofilms, Rome, Italy. September 4, 2009.

“Vaccine development and the host immune response to Staphylococcus aureus biofilms. Eurobiofilms, Rome, Italy. September 4, 2009.

“Vaccines against Staphylococcus aureus biofilms.” Gordon Conference of Staphylococcus aureus. New Hampshire. September 1, 2009.

“Biofilms and chronic wound infections.” Symposium on Advanced Wound Care/Wound Healing Society. Dallas, TX. April 29, 2009.

“Role of the host and the pathogen in musculoskeletal infections.” Musculoskeletal Infection Society Annual Meeting. August 7-8, 2009.

“Staphylococcus aureus biofilms” Food and Drug Administration. Bethesda, Maryland. April 14, 2009.

“Biofilm Infections: A case study of Staphylococcus aureus pathogenesis.” University of Ottawa, Ottawa, Canada. March 3, 2009.

“Staphylococcus aureus Biofilm Infections: Host immune response and vaccine development.” National Research Council of Canada. Ottawa, Canada. March 2, 2009.

 “Animal models of Staphylococcus aureus chronic biofilm infections” 5th ASM Conference on Biofilms. Cancun, Mexico. November 15 - 19, 2009.

“Controversies in Infection: Diagnosing and Treating.” 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) Meeting. Dallas, Texas. April 26-29, 2009.

“Sensing and biofilms – biofilm effect on antimicrobial agents and effect of antibacterial agents on biofilm formation.” 48^th Interscience Conference on Antimicrobial Agents and Chemotherapy/46^th Infectious Disease Society of America Joint Annual Meeting, Washington, D.C. October 25-28, 2008.

“Host-Pathogen Interactions in Biofilm Infections” Session Convener. 108^th General Meeting of the American Society for Microbiology, Boston, Massachusetts, June 1-5, 2008.

“Host Immune Response in Chronic Staphylococcus aureus Biofilm Infections” 108^th General Meeting of the American Society for Microbiology, Boston, Massachusetts, June 1-5, 2008.

“Biofilm-Mediated MRSA Infections: Slime by Design” Division of Infectious Diseases, Johns Hopkins University – School of Medicine, Baltimore, Maryland, April 21, 2008.

“Biofilms and Polymicrobial Infections” Division of Infectious Diseases, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, January 9, 2008.

“Persistent Biofilm Infections” Department of Ophthalmology, Harvard Medical School, and The Schepens Eye Research Institute, Boston, Massachusetts, November 1, 2007.

 “The Role of Biofilms on Chronic Infectious Diseases, with Special Focus on Bone and Joint Infections” Mayo Clinic, Rochester, MN, September 4, 2007.

“The Role of Biofilms in Chronic Infection” Department of Molecular Microbiology and Immunology, University of Missouri Medical School, Columbia, Missouri, August 20, 2007.

“Biofilms in Orthopaedic Infections” Department of Orthopaedics, University of Missouri Medical School, Columbia, Missouri, May 23, 2007.

 “The Role of Biofilms in Chronic Infections” Center for Genomic Sciences, Allegheny General Hospital, Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, December 11, 2006.

“The Role of Biofilms in Chronic Orthopaedic Infections” Annual Meeting of the Japanese Orthopaedic Society, Nagasaki, Japan, October 18-19, 2006.

“The Use of a Denaturing HPLC Modification of the DGGE Technique for the In Situ Analysis of Complex Bacterial Populations in Health and Disease” ASM General Meeting, Orlando, Florida, May 21-25, 2006.

“Staphylococcus aureus biofilms: in vitro and in vivo studies” Annual Research Symposium. Joan C. Edwards School of Medicine Marshall University, Huntington, West Virginia. March 20, 2006.

“Staphylococcus aureus Infections” Northern Arizona University, Flagstaff, Arizona. March 13, 2006.

“Role of Biofilms in Osteomyelitis” Philips Oral Healthcare Biofilm Symposium. University of Southern California, Los Angeles, California, Oct. 24-25, 2005.

 “The HPLC Modification of the DGGE Method for Population Analysis” Philips Oral Healthcare Biofilm Symposium. University of Southern California, Los Angeles, California, Oct. 24-25, 2005.

“Molecular methods for the analysis of biofilm communities” Philips Oral Healthcare Biofilm Symposium. University of Southern California, Los Angeles, California, Oct. 24-25, 2005.

“Studies on Staphylococcus aureus Biofilms.” 2005 Summer Symposium: Bugs and Biomaterials: Bacteria and the Biointerface. University of Washington · Seattle, WA August 24 - 26, 2005.

“Detachment and Host Antibody Response to Staphylococcus aureus Biofilm Infections” Center for Biofilm Engineering, Montana State University, Bozeman, MT, March 3, 2005.

 “The Clinical Impact of Biofilm Infections” Winthrop University Hospital, Mineola, NY, February 3, 2005.

“Biofilms and Device Related Infections”, Southwestern Association of Clinical Microbiology, Yearly Scientific Meeting. San Antonio, TX, September 16, 2004.

 “The Importance of Biofilms in Battlefield Injuries”, Management of Battlefield Tissue Injury, Toronto, Canada, June 28, 2004.

“Staphylococcal biofilms” Northern Arizona University, Flagstaff, AZ, April 26, 2004.

“Antimicrobial Resistance and Implications for Antibiotic-Impregnated Bone Cement” Stryker Howmedica Osteonics, Mahwah, NJ, April 21, 2004.

“Workshop on Proteomics and Applications in Biofilm Research” La Sapienza University, Rome, Italy, March 29 – April 5, 2004.

“Microbial proteomics: Workshop on sample preparation, two-dimensional gel electrophoresis, and mass spectrometric analysis” Concepcion, Chile, January 12-16, 2004.

“Staphylococcus aureus and biofilms” National Institutes of Health, Washington DC, December 15, 2003.

 “Biofilms and their role in chronic infections” Columbia University, New York, NY, December 1, 2003.

“Proteomic evaluation of Staphylococcus aureus biofilms” American Society for Microbiology Biofilms 2003, Victoria, Canada, November 3, 2003.

“Proteomic and genomic evaluation of Staphylococcus aureus biofilms” Society of Industrial Microbiology, 2003 Annual Meeting, Minneapolis, Minnesota, August 12, 2003.

 “Evaluation of Staphylococcus aureus biofilms” Department of Microbiology, University of New Hampshire, May 6, 2003.

“Staphylococcus aureus biofilms” Departments of Environmental Engineering and Biotechnology, Aalborg University, Denmark, April 7, 2003.

“A search for vaccines against staphylococcal biofilm-mediated infections” Department of Microbiology, Danish Technological University, Copenhagen, Denmark, April 1, 2003.

“Using microarrays to determine the gene expression profiles in biofilms” Danish Technological Institute, Denmark, April 3, 2003.

“Treatment of osteomyelitis and septic arthritis: Evidences from animal models” Treatment of Bone and Joint Infections, 1^st Annual Meeting of the Italian Society for Anti-infective Therapy, Vicenza, Italy, March 28, 2003.

“Hyperbaric oxygen therapy and the treatment of musculoskeletal infections” Treatment of Bone and Joint Infections, 1^st Annual Meeting of the Italian Society for Anti-infective Therapy, Vicenza, Italy, March 28, 2003.

“Proteomic, microarray, and host-pathogen interaction studies of Staphylococcus aureus biofilms” University of Maryland, Departments of Oral and Craniofacial Biological Sciences, February 26, 2003.

“Staphylococcus aureus biofilms” Genome Therapeutics, Waltham, Massachusetts, February 20, 2003.

“Biofilms of staphylococci” New York Medical College. Department of Microbiology and Immunology, December 9, 2002.

“Biofilms: Properties, significance, and current research” Department of Environmental Engineering, Washington State University, December 2, 2002.

“Proteomics, genomics, and host-pathogen interactions in Staphylococcus aureus biofilms” Department of Microbiology, Montana State University, October 11, 2002.

“Staphylococcus aureus biofilms” Veterinary Molecular Biology, Montana State University, September 10, 2002.

Back to Top

Associate Professor

Department of Microbial Pathogenesis

Dental School, University of Maryland – Baltimore

July 2009 - present

Associate Professor (secondary appointment)

Department of Microbiology and Immunology

Medical School, University of Maryland - Baltimore

January 2010 - present

Assistant Professor

Department of Biomedical Sciences

Dental School, University of Maryland – Baltimore

Sept 2003 – June 2009

Assistant Professor (secondary appointment)

Department of Microbiology and Immunology

Dental School, University of Maryland – Baltimore

Jan 2004 - present

Assistant Research Professor

Department of Microbiology & The Center for Biofilm Engineering

Montana State University

Oct 2002 - Aug 2003

Postdoctoral Fellow

Center for Biofilm Engineering

Montana State University

Advisor: Dr. AK Camper

Oct 2000 - Oct 2002

Graduate Student and Laboratory Director

Dept. of Marine Biomedical Institute

U of Texas Medical Branch

Advisor: Dr. JT Mader

Sept 1995 - Sept 2000

Research Assistant

Dept. of Microbiology and Immunology

U of Texas Medical Branch

Supervisor: Dr. CP Davis

June 1993 - April 1995

Instructor and Coordinator, MICP 521 – General & Orofacial Infectious Diseases, University of Maryland, Baltimore. Fall, 2009 – present.

Instructor and Coordinator, MMIC 701 – Principles of Bacterial Pathogenesis, University of Maryland, Baltimore. Spring, 2005 – present. (Coordinator since 2011).

Instructor, MSPR 520 – Host Defenses and Infectious Diseases, University of Maryland, Baltimore. Fall, 2006 – present.

Instructor, BSCI-511 – Cell and Molecular Biology, University of Maryland, Baltimore. Fall 2006 – present.

Instructor, DBMS 511M – Microbiology and Immunology, University of Maryland, Baltimore. Spring 2004 - present.

Back to Top

Current Grants (given in direct costs)

“Staphylococcus aureus biofilms: in vitro and in vivo studies” National Institutes of Health – R01-AI069568-02. PI – Mark E. Shirtliff. $1,250,000 (+ $606,250 Indirects). June 1, 2007 –May 31, 2012.

Staphylococcus aureus biofilms: in vitro and in vivo studies. National Institutes of Health (Agency NIAID) – R01-ARRA Supplement. PI – ME Shirtliff. August 2010 – August 2011. $321,000

“Vaccine development for recurrent musculoskeletal infections” Department of Defense. – W81XWH-07-1-0210. PI – ME Shirtliff. $280,000 (+ $70,000 Indirects). Sept 1, 2008 –Aug 31, 2010.

“Candida albicans and Staphylococcus aureus biofilms: in vitro and in vivo studies” National Institutes of Health. 1R01DE020939-01A2. PI – Mary Ann Jabra-Rizk, Co-PI - Mark E. Shirtliff. $1,125,000 (+ $562,500 Indirects). $125,000/yr to Shirtliff Lab. July 1, 2010 - June 30, 2015.

“Determination of differential gene expression in Staphylococcus aureus biofilms through microarray analysis.” National Institutes of Health. PI – ME Shirtliff. $200,000 in material costs only – no indirects provided. June 1, 2006 – present.

“Determination of differential gene expression in Candida albicans biofilms through microarray analysis.” National Institutes of Health. PI – ME Shirtliff. $200,000 in material costs only – no indirects provided. June 1, 2006 – present.

Back to Top